dimanche 15 novembre 2026
RechercherExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each, so you can check any claim. How we source
Source document· April 23, 2026

The Best Artificial Intelligence (AI) Growth Stocks on the Nasdaq That Wall Street Loves Right Now

View original at nasdaq.com
The Best Artificial Intelligence (AI) Growth Stocks on the Nasdaq That Wall Street Loves Right Now Key Points Wall Street analysts love these two artificial intelligence (AI) stocks…
Opening lines of the source · short snapshot: read the full document at the original

Ce que nous avons tiré de cette source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Applied Digital is targeting $1 billion in net operating income (NOI) over the next five years

    60% confidence
  • Interest is high among hyperscalers for all of these new facilities

    60% confidence
  • If you invested $1,000 in Netflix on December 17, 2004, you'd have $502,837

    60% confidence
  • Roughly 93% of the 70 analysts who cover Nvidia say it is a buy with a median price target of $267.50, suggesting about 33% upside

    60% confidence
  • Stock Advisor's total average return is 977% compared to 200% for the S&P 500

    60% confidence
  • If you invested $1,000 in Nvidia on April 15, 2005, you'd have $1,241,433

    60% confidence
  • 100% of the 13 analysts that cover Applied Digital rate it a buy, with a median price target of $43 per share, suggesting 32% upside

    60% confidence
  • Some $4 trillion is projected to be spent on data centers in 2030 worldwide, up from $1 trillion in 2025

    60% confidence

Data points we hold from this source

S&P 500 · return200 percent
Ce que nous savons · l'intelligence derrière cette page
En direct du substrat
Ce que nous observons
Q4 2026 Biotech Catalyst Cluster: Late-Stage Data and PDUFA Dates Converge
Early-to-mid November 2026 is a dense run of clinical readouts and Q3 earnings at AHA, AASLD, ACR and ASH. Mid-cap biotechs (Vir, Mineralys, Arrowhead, Oryzon, Novartis, J&J) are reporting data that feeds into regulatory decisions. The next ones are the ivonescimab BLA (Nov 14) and the lorundrostat PDUFA (Dec 22), followed by ECLIPSE 2/3 and Maritime-1 readouts in Q1 2027. The list also includes an unrelated delisting track (EGM Nov 19, application Jan 25, 2027), and the facts have no AI or fintech content.
Notre lecture des données ›
Signaux que nous suivons
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Tendances que nous surveillons ›
Là où les sources divergent
Sources réconciliées : aucun conflit ouvert pour l'instant.
Nous signalons les conflits ouvertement ›
Vérifié récemment
✓ Vérifié avec la source d'origine
4,959
faits reliés à leur source, et nous signalons ceux qui ne tiennent pas.
101 entités suivies4,959 faits vérifiés avec la source5,585 documents sources archivés
Interrogez ces données → isubstrate.com
The Best Artificial Intelligence (AI) Growth Stocks on the Nasdaq That Wall Street Loves Right Now: Source | Via News | fr.via.news